文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙肝后肝细胞癌的长期风险

Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.
PubMed 文献 · Hepatology · 2019-08-19

该回顾性队列研究纳入2015年在129家退伍军人医院接受直接抗病毒药物(DAA)治疗并达到持续病毒学应答(SVR)的18,076例丙肝患者,随访至2018年9月。平均随访2.9年期间诊断544例肝细胞癌(HCC),1、2、3年累积风险分别为1.1%、1.9%、2.8%;肝硬化与HCC风险强烈相关(调整风险比=4.13,95%CI=3.34-5.11)。

要点

  • DAA治疗后达到SVR的丙肝患者仍有HCC风险,肝硬化者风险显著更高。
  • 肝硬化患者HCC季度发生率维持在1.5-2.3/100人年,未随时间下降。
  • FIB-4/APRI持续升高者HCC风险最高,肝硬化患者指标下降后风险仍高于监测阈值。

核心结论

  • 成功接受DAA治疗的丙肝患者中,有HCC风险者在3.6年随访后风险并未消退;肝硬化患者的HCC风险仍高于公认的监测阈值。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月1日至2015年12月31日期间在129家退伍军人健康管理局医院接受DAA治疗并达到SVR的丙肝患者,随访至2018年9月30日,共18,076例。

主要发现

  • 平均随访2.9年期间诊断544例HCC,累积1年、2年、3年HCC风险分别为1.1%、1.9%、2.8%。
  • 肝硬化与HCC风险强烈相关(调整风险比=4.13,95%CI=3.34-5.11)。
  • HCC季度发生率在1.00-1.23/100人年之间保持稳定,肝硬化患者为1.5-2.3/100人年。
  • FIB-4/APRI持续升高的患者HCC风险最高,无论有无肝硬化;肝硬化患者FIB-4/APRI下降后HCC风险降低,但仍高于公认的HCC监测阈值。
  • 酒精使用、年龄较大和HCV基因3型感染患者HCC风险也较高;大多数肝纤维化早期接受治疗的患者风险稳定且低。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long-term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with follow-up through September 30, 2018. We calculated the overall and quarterly HCC incidence rates. We examined the effect of demographic, clinical, and behavioral factors and the decline or increase of FIB-4 and aspartate aminotransferase to platelet ratio index (APRI) on HCC risk. Among the 18,076 patients with SVR, 544 incident cases of HCC were diagnosed during the mean 2.9 years of follow-up. The cumulative 1, 2, and 3-year risks of HCC were 1.1%, 1.9% and 2.8%, respectively. Cirrhosis was strongly associated with HCC risk (adjusted hazard ratio = 4.13, 95% confidence interval = 3.34-5.11). The quarterly incidence rate of HCC remained stable between 1.00 and 1.23/100 person-years (PY) and 1.5 to 2.3/100 PY in patients with cirrhosis. The risk of HCC was the highest in patients who had persistently high FIB-4/APRI and both with and without cirrhosis. HCC risk fell in patients with cirrhosis who experienced a decrease of FIB-4/APRI scores yet remained higher than the accepted threshold for HCC surveillance. HCC risk was also higher in patients with alcohol use, older age, and infection with HCV genotype 3. Most patients treated at an early stage of liver fibrosis had a stable low risk. Conclusion: Patients successfully treated with DAAs and at risk of HCC did not regress after 3.6 years of follow-up. HCC risk remained above the accepted thresholds for surveillance in patients with cirrhosis. These data have important implications for HCC surveillance in cured HCV patients.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Kramer JR, Asch SM, et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2019. PMID: 31222774. doi:10.1002/hep.30823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。